Literature DB >> 21053363

Macrophage inflammatory protein-1α induces osteoclast formation by activation of the MEK/ERK/c-Fos pathway and inhibition of the p38MAPK/IRF-3/IFN-β pathway.

Masanobu Tsubaki1, Chisato Kato, Ai Isono, Junichi Kaneko, Misako Isozaki, Takao Satou, Tatsuki Itoh, Yasuhiro Kidera, Yoshihiro Tanimori, Masashi Yanae, Shozo Nishida.   

Abstract

Multiple myeloma (MM) is a bone disease that affects many individuals. It was recently reported that macrophage inflammatory protein (MIP)-1α is constitutively secreted by MM cells. MIP-1α causes bone destruction through the formation of osteoclasts (OCs). However, the molecular mechanism underlying MIP-1α-induced OC formation is not well understood. In the present study, we attempted to clarify the mechanism whereby MIP-1α induces OC formation in a mouse macrophage-like cell line comprising C7 cells. We found that MIP-1α augmented OC formation in a concentration-dependent manner; moreover, it inhibited IFN-β and ISGF3γ mRNA expression, and IFN-β secretion. MIP-1α increased the expressions of phosphorylated ERK1/2 and c-Fos and decreased those of phosphorylated p38MAPK and IRF-3. We found that the MEK1/2 inhibitor U0126 inhibited OC formation by suppressing the MEK/ERK/c-Fos pathway. SB203580 induced OC formation by upregulating c-fos mRNA expression, and SB203580 was found to inhibit IFN-β and IRF-3 mRNA expressions. The results indicate that MIP-1α induces OC formation by activating and inhibiting the MEK/ERK/c-Fos and p38MAPK/IRF-3 pathways, respectively, and suppressing IFN-β expression. These findings may be useful in the development of an OC inhibitor that targets intracellular signaling factors.
© 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21053363     DOI: 10.1002/jcb.22907

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  10 in total

1.  RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications.

Authors:  Antonio Garcia-Gomez; Enrique M Ocio; Atanasio Pandiella; Jesús F San Miguel; Mercedes Garayoa
Journal:  Invest New Drugs       Date:  2012-07-07       Impact factor: 3.850

Review 2.  Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics.

Authors:  Antonio Garcia-Gomez; Fermin Sanchez-Guijo; M Consuelo Del Cañizo; Jesus F San Miguel; Mercedes Garayoa
Journal:  World J Stem Cells       Date:  2014-07-26       Impact factor: 5.326

3.  Inhibition of osteoclast differentiation and bone resorption by N-methylpyrrolidone.

Authors:  Chafik Ghayor; Rita M Correro; Katrin Lange; Lindsay S Karfeld-Sulzer; Klaus W Grätz; Franz E Weber
Journal:  J Biol Chem       Date:  2011-05-25       Impact factor: 5.157

4.  Bisphosphonates and statins inhibit expression and secretion of MIP-1α via suppression of Ras/MEK/ERK/AML-1A and Ras/PI3K/Akt/AML-1A pathways.

Authors:  Masanobu Tsubaki; Tomoya Takeda; Kotaro Sakamoto; Hirotaka Shimaoka; Arisa Fujita; Tatsuki Itoh; Motohiro Imano; Kenji Mashimo; Daiichiro Fujiwara; Katsuhiko Sakaguchi; Takao Satou; Shozo Nishida
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

Review 5.  Multiple Myeloma and Bone: The Fatal Interaction.

Authors:  Silvia Marino; G David Roodman
Journal:  Cold Spring Harb Perspect Med       Date:  2018-08-01       Impact factor: 6.915

6.  Metformin Improves Diabetic Bone Health by Re-Balancing Catabolism and Nitrogen Disposal.

Authors:  Xiyan Li; Yuqi Guo; Wenbo Yan; Michael P Snyder; Xin Li
Journal:  PLoS One       Date:  2015-12-30       Impact factor: 3.240

7.  Stimulation of osteoclast formation by RANKL requires interferon regulatory factor-4 and is inhibited by simvastatin in a mouse model of bone loss.

Authors:  Yoshiki Nakashima; Tatsuji Haneji
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

8.  Nitrogen-containing bisphosphonates inhibit RANKL- and M-CSF-induced osteoclast formation through the inhibition of ERK1/2 and Akt activation.

Authors:  Masanobu Tsubaki; Makiko Komai; Tatsuki Itoh; Motohiro Imano; Kotaro Sakamoto; Hirotaka Shimaoka; Tomoya Takeda; Naoki Ogawa; Kenji Mashimo; Daiichiro Fujiwara; Junji Mukai; Katsuhiko Sakaguchi; Takao Satou; Shozo Nishida
Journal:  J Biomed Sci       Date:  2014-02-03       Impact factor: 8.410

Review 9.  Roles of Mitogen-Activated Protein Kinases in Osteoclast Biology.

Authors:  Kyunghee Lee; Incheol Seo; Mun Hwan Choi; Daewon Jeong
Journal:  Int J Mol Sci       Date:  2018-10-01       Impact factor: 5.923

10.  The HGF/Met/NF-κB Pathway Regulates RANKL Expression in Osteoblasts and Bone Marrow Stromal Cells.

Authors:  Masanobu Tsubaki; Shiori Seki; Tomoya Takeda; Akiko Chihara; Yuuko Arai; Yuusuke Morii; Motohiro Imano; Takao Satou; Kazunori Shimomura; Shozo Nishida
Journal:  Int J Mol Sci       Date:  2020-10-24       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.